17,261 trials
Psoriasis
Primary: Mean Percent Change From Baseline in the Psoriasis and Activity Severity Index (PASI) Score at Day 29 — -3.30; -2.14 Score on a Scale
Alveolitis, Fibrosing · Fibrosis, Pulmonary · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Test — -26; -7 meters
Lung Cancer · Non-Small-Cell Lung Carcinoma
Primary: Determine Objective Response Rate — 0; 5; 14; 9 patients
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 3 to 7 Hours (AUC3-7hr) After Allergen Challenge Following 9 Days…
Macular Edema · Branch Retinal Vein Occlusion
Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart
Adenocarcinoma of the Bladder · Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Tumor Response Rate — 4.5 percentage of responders
Ciliary Body and Choroid Melanoma, Medium/Large Size · Extraocular Extension Melanoma · Iris Melanoma
Primary: Objective Response Rate Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) — 2 participants
Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: PSA Response Rate — 0 percentage of participants
Peripheral Neuropathy
Primary: Identification of the Optimal Dose of ALA Based on Acceptable Adverse Event(AE) Profile — 500 mg
Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Overall Response Rate — 10; 10 percentage of participants
Recurrent Non-small Cell Lung Cancer
Primary: Objective Response Rate — 0; 0 percentage of responding patients
Stage III Gastric Cancer · Stage IV Gastric Cancer
Primary: Observed Response Rate. — 0 Percentage of Participants
Heart Failure, Congestive
Primary: Change From Baseline in Myocardial Glucose Utilization as Assessed by [18F]Fluoro-2-deoxy-glucose Positron Emission Tomography (FDG-PET) Imaging — 0.0185; 0.0103…
Hepatitis C · HIV
Primary: Part A: Plasma Pharmacokinetics of SOF, EFV, Tenofovir (TFV), and FTC: AUCtau at Day 7 — 867.5; 627.6; 2269.4; 1421.5 h*ng/mL